176
Participants
Start Date
March 2, 2022
Primary Completion Date
July 31, 2024
Study Completion Date
July 31, 2027
Neoadjuvant Chemoradiotherapy
"Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.~Radiotherapy: A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 days per week (Radiotherapy was performed on the 2nd, 3rd, 4th, 5th, and 6th day in each cycle, and only 3 times in the 5th cycle)"
Tislelizumab
"Tislelizumab (200mg/time) was administered intravenously on the 1st and 22nd day.~The intravenous injection lasts about 30 minutes (micropump is recommended, intravenous bolus is prohibited, duration should be not less than 20 minutes and not more than 60 minutes);"
Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)
After neoadjuvant therapy, patients in groups receive Ivor-Lewis or Mckeown Esophagectomy (Mckeown Esophagectomy recommended)
RECRUITING
Shanghai Zhongshan Hospital, Shanghai
Peking University Cancer Hospital & Institute
OTHER
Shanghai Chest Hospital
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
The First People's Hospital of Changzhou
OTHER
Zhongshan Hospital (Xiamen), Fudan University
OTHER
Xuhui Central Hospital, Shanghai
OTHER
Shanghai Minhang Central Hospital
OTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Zhejiang Cancer Hospital
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
Tongji Hospital
OTHER
Sun Yat-sen University
OTHER
Shanghai Fifth People's Hospital
UNKNOWN
Shanghai Zhongshan Hospital
OTHER